Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia
Walker S, Palmer S, Erhorn S, Brent S, Dyker A, Ferrie L, Horsley W, Macfarlane K, White S, Thomas S
Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Citation
Walker S, Palmer S, Erhorn S, Brent S, Dyker A, Ferrie L, Horsley W, Macfarlane K, White S, Thomas S. Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia. Health Technology Assessment 2009; 13(Suppl 1 Article 6): 35-40
Authors' conclusions
To enable an accurate assessment to be made of the clinical and cost-effectiveness of fludarabine as first-line treatment for chronic lymphocytic leukaemia there is a need for further evidence to clarify areas of uncertainty.
NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk